PTPRC and neoplasm: On Day 6, neutrophils in VSV-S-treated tumors were increased by 7–10 folds, occupying over 50% in the total tumor-infiltrating leukocytes (CD45 +), and this phenomenon of neutrophil infiltration continued to Day 12 when the tumor burden was further reduced.